BIO-TECHNE Corp (TECH): what the price requires
At today's price, BIO-TECHNE Corp (TECH) is priced for today's economics sustained for ~11.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/TECH
Headline
| Field | Value |
|---|---|
| Ticker | TECH |
| Company | BIO-TECHNE Corp |
| Sector / Industry | Healthcare |
| Current price | $71.40/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 32.9% |
| Operating margin today | 17.9% |
| Margin expansion implied | +15.0pp |
| Must persist for | 11.4y |
| Multiple paid | 43x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 10.6% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.1 years.
Reconcile: at the x-ray's 9.3% required return this reads ~8.7 years; the models below use their own rates.
How unusual the bet is: high
| Reference | Value |
|---|---|
| vs own history | +1.08σ |
| cohort percentile (of 112 peers) | 88 |
| sustained it ~10 years at this level | 14% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 13.32x | 5 | expensive |
| Earnings | 6.32x | 5 | expensive |
| Relative | 3.19x | 4 | expensive |
| Growth | 1.84x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.
Per-Model Detail (n=17)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $18.86 | 3.79x | yes | FCF base $0.3B, growth 0% (input: historical growth), terminal g 0.5%, WACC 9.0%, 5yr projection |
| DCF Exit Multiple | Growth | $55.23 | 1.29x | yes | Exit EV/EBITDA: 61.6x / 63.6x / 65.6x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $33.52 | 2.13x | yes | P/E 47.57x (blended: static sector reference 24x + trailing (TTM) 103x), scenarios: 40.4x / 47.6x / 54.7x (bear / base = reference held flat / bull), EV/EBITDA 30.27x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $7.53 | 9.48x | yes | BV/sh $13.25, ROE (TTM) 5.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $5.36 | 13.32x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $38.79 | 1.84x | yes | Rev $1.2B, growth 0% (input: historical growth; tapered), Terminal P/S: 6.8x / 8.0x / 9.2x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $8.28 | 8.62x | yes | EPS $0.69, growth 2% (input: historical EPS growth), PEG=42.56 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $11.30 | 6.32x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.24B × (1−28%) / WACC 9.0% → EPV (no growth) |
| Residual Income | Asset | $5.11 | 13.97x | yes | BV $13.25 + 5yr PV of (ROE (TTM) 5.3% − Kₑ 9.3%) × BV; BV grows 3.4%/yr |
| Graham Number | Asset | $14.34 | 4.98x | yes | √(22.5 × EPS $0.69 × BVPS $13.25) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $17.59 | 4.06x | yes | EBITDA $0.18B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $18.01 | 3.96x | yes | FCF $269.6M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $15.21 | 4.69x | yes | SBC-adj FCF $0.23B (FCF $0.27B − SBC $0.04B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $7.70 | 9.27x | yes | EPS $0.69 × (8.5 + 2×2.4%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $3.66 | 19.51x | yes | BV $13.25 × (ROIC 2.5% / WACC 9.0%) |
| P/Sales Sector | Relative | $30.77 | 2.32x | yes | Revenue $1.21B × sector P/S 4.0x |
| PEG Fair Value | Relative | $3.45 | 20.70x | yes | EPS $0.69 × (PEG 1.5 × growth 2.4% (input: historical EPS growth)) → PE 3.6x (excluded from median) |
| Earnings Yield | Earnings | $7.46 | 9.57x | yes | EPS $0.69 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $9.8m |
| Net debt / NOPAT (after-tax) | -0.06x (net cash) |
| Net debt / operating income (pre-tax) | -0.05x (net cash) |
| Interest coverage | 22.7x |
| Share count CAGR (buyback) | -1.0% |
| Burning cash | no |
Bullet Takeaways
- Bio-Techne sells the reagents, antibodies, and assays that life-science labs consume, a razor-and-blade catalog where the Protein Sciences segment alone accounted for more than 10 percent of segment net sales across three straight fiscal years, giving the business unusually sticky, recurring demand.
- The defining risk is the price: at about 43 times company-wide operating income, no valuation family, asset, earnings, peer, or forward growth, reaches today's level, so the stock is priced for roughly a decade of top-ceiling growth against a business that recently posted flat-to-down organic revenue.
- The near-term swing factor is the recovery in academic and emerging-biotech spending, which the FY2025 10-K notes "can fluctuate due to changes in available resources"; the fiscal fourth quarter (ending June 30, 2026) is the next print, with management guiding roughly flat year-over-year growth.
Bull Case
The structural advantage here is boring in the best way. Bio-Techne makes the consumables, proteins, antibodies, immunoassays, and spatial-biology reagents, that biology labs order again and again, and a business built on repeat consumption of specialized inputs enjoys switching costs that show up as pricing power. Its own 10-K concedes the market is crowded, noting it is "difficult to determine our competitive position" in "highly competitive markets", yet the durability shows in the concentration disclosure: the Protein Sciences segment accounted for more than 10 percent of the segment's net sales in fiscal 2025, 2024, and 2023, a base that persists across cycles because a validated reagent embedded in a lab's protocol is expensive to swap out. The peer set, Repligen, IDEXX, QIAGEN, Maravai, competes for adjacent life-science and diagnostics budgets, but a validated antibody catalog is not a commodity the way a tracker or a sequencer consumable is.
The growth engine is spatial biology. Management reported the segment growing mid-teens, led by more than 65 percent growth in the COMET platform, with the RNAscope portfolio up high single digits, and it expects margin expansion as COMET scales. This is the part of the catalog that turns Bio-Techne from a mature reagent supplier into a franchise selling instruments and the consumables that run on them, which is the razor-and-blade model applied to the fastest-growing corner of biology research. The 10-K frames the strategy plainly, warning that if the company were to "fail to produce viable technologies, we may invest heavily in research and development of products that do not lead to significant revenue", which is exactly the bet spatial is meant to win.
The balance sheet gives management room to keep buying growth. Net debt is essentially nil, interest coverage sits near 16 times, and the share count has actually declined about 1 percent a year over four years, so dilution is not eating the story. That footing supports the tuck-in acquisition strategy the filing describes, with its "contingent payments" tied to "financial performance based milestones, projected revenue and/or EBITDA". A clean balance sheet, a recurring-consumables core, and a genuine growth vector in spatial biology is a combination that can compound quietly. The question the bull has to answer is not whether the business is good; it is whether it is good enough to earn the price.
Bear Case
The most demanding thing about Bio-Techne is not its debt but its capital structure in the widest sense: the market has capitalized this business at a level that assumes flawless compounding, and the recent operating record does not yet support it. At about 43 times company-wide operating income, the price requires operating growth to hold near its self-funding ceiling for roughly twelve years. Set that against what the company is actually delivering. Fiscal third-quarter revenue came in at $311.4 million, below the roughly $316 million expected, with Protein Sciences down 1 percent and organic revenue down 4 percent, and the diagnostics-and-spatial segment down 4 percent on a reported basis. A stock priced for a decade of top-ceiling growth is posting flat-to-negative organic numbers. That gap is the bear case in one line.
The demand side is outside management's control, and the balance-sheet-adjacent fragility is that so much of the revenue leans on discretionary research budgets. The 10-K states that "spending by our customers and the availability of government research funding can fluctuate due to changes in available resources", and management's own commentary pinned the weakness on emerging-biotech spending, with a 150 basis point headwind from Fast Track customers flagged into the fourth quarter. When a large share of the top line depends on academic grant cycles and venture-funded biotech, a funding air pocket flows straight to organic growth, and the price has no cushion for it.
The valuation math is unforgiving from every angle. Book value sits near $13.25 per share against a $71.29 price, trailing return on equity is only about 5.3 percent, below the roughly 9.3 percent cost of equity, and on that spread the residual-income and ROIC-justified approaches land far below the price, because a business earning less than its cost of capital is not creating book value fast enough to justify a premium to it. Even the friendliest lenses do not close the gap: a zero-growth capitalization of current free cash flow supports a value roughly a quarter of the price. Wall Street's own consensus target of about $67.60 sits below today's price, which is a rare tell that the street sees more downside than up. The bear does not need a catastrophe. It only needs the growth reacceleration to arrive later, or smaller, than 43 times operating income demands.
Valuation
Start with what the price is betting. At $71.29 the market pays about 43 times company-wide operating income, which inverts to a bet that operating growth holds near its self-funding ceiling for roughly twelve years. Keep those figures approximate; they are one internally consistent solve, not a measurement. Two references frame how demanding it is: the multiple sits at the very top of the peer distribution, well beyond the upper quartile, and of comparable fast-growers only about 14 percent sustained that kind of pace for a decade. The near-term rate is within what Bio-Techne has delivered before; the stretch is entirely in how long it must persist.
What is unusual is that no family of method reaches the price. Asset-based approaches, anchored on book value near $13.25 and a trailing return on equity around 5.3 percent that trails the cost of equity, land a large multiple below the price. Earnings-power methods, capitalizing normalized operating profit with no growth, sit several times under it. When every lens agrees the stock is rich and only disagrees on the degree, the price is a bet beyond what any standard frame supports. That is the pattern, and it is worth stating plainly rather than dressing up.
One measurement note matters for coherence: the operating income the price is read against, on the record basis, is roughly $258 million, while the EDGAR trailing read is about $154 million; the two bases diverge by more than half and should not be mixed, so the 43 times figure travels with the record basis it was computed on. On solvency the picture is clean and does not bound the downside meaningfully: net debt is essentially zero, liquid assets of about $210 million cover the $200 million of gross debt, interest coverage is near 16 times, and the share count has fallen about 1 percent a year. The risk here is not the balance sheet. It is that the price already assumes the reacceleration, so the reacceleration has to be not just real but durable, and the street's own mean target near $67.60 already sits below the price.
Catalysts
Bio-Techne reported fiscal third-quarter results on May 6, 2026, covering the quarter ended March 31. Revenue of $311.4 million came in below the roughly $316 million expected, and adjusted EPS of $0.53 narrowly missed a $0.54 estimate, yet the stock rose on the print as investors focused on the spatial-biology momentum and margin narrative. The segment detail was mixed: Protein Sciences at $226.2 million, down 1 percent (organic down 4 percent), and Diagnostics and Spatial Biology at $85.6 million, down 4 percent reported but up 3 percent organic with margin expansion.
The growth story management is pointing to is spatial: mid-teens segment growth, more than 65 percent growth in the COMET platform, and high-single-digit growth in RNAscope, with continued margin expansion expected as COMET scales. The offsetting drag is end-market: strong large-pharma demand and stabilizing U.S. academic trends against continued weakness in emerging-biotech spending, plus a roughly 150 basis point Fast Track headwind carried into the fourth quarter.
The next dated event is fiscal fourth-quarter results, covering the quarter ended June 30, 2026, expected in early August. Management guided to roughly flat year-over-year growth for that quarter and framed fiscal 2027 as the recovery year on biotech stabilization and easier comparisons. The watch items are the trajectory of organic growth, evidence the COMET ramp keeps compounding, and any firming in academic and emerging-biotech funding, which is the swing variable the price has the least room to absorb.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- RGEN (REPLIGEN CORP)
- (no filing in the citation store)
- IDXX (IDEXX LABORATORIES INC /DE)
- (no filing in the citation store)
- QGEN (QIAGEN N.V.)
- (no filing in the citation store)
- MRVI (Maravai LifeSciences Holdings, Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q3 FY2026 earnings call, May 6, 2026 · Q3 FY2026 earnings release, May 6, 2026 · Public.com analyst data, June 2026 · Q3 FY2026 earnings release and TipRanks coverage, May 2026